Tom Wilder currently serves on the Boards of Penumbra (PEN), Endologix (ELGX), and Benvenue Medical. Until its acquisition for up to $380M by Terumo in 2016, Tom served as CEO of Sequent Medical, Inc. Prior to this, he served as CEO for PhotoThera, Inc. From 2002 to 2006, Tom served as CEO of MicroTherapeutics, Inc. (MTIX), which was merged into ev3 (EVVV) at a valuation of $360M. From 1991 to 2002, Tom held positions of increasing responsibility at Medtronic (MDT), most recently as VP and General Manager of its endovascular stent grafts division. Tom has a B.A. from Stanford University and an M.B.A. from Northwester University’s J.L. Kellogg Graduate School of Management.